Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01554787

Enrollment

Registered

2012-03-15

Start date

2012-01-31

Completion date

Unknown

Last updated

2012-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue, Stroke

Keywords

After stroke with fatigue

Brief summary

The high levels of fatigue in stroke patients without neurological impairment suggest it has a central origin rather than being the result of increased physical effort required after stroke（Winward et al., 2009）. Fatigue is different from post-stroke depression and the more serious stroke patients are more prone to fatigue（Windward et al., 2009）. Fatigue is one of the symptoms of qi deficiency,and Astragalus membranaceus is the most effective of all traditional Chinese medicine and can tonifying middle and tonify the original qi. Therefore, the aim of this study was to investigate the efficacy of Astragalus membranaceus on post-stroke fatigue.

Interventions

DRUGChinese Herb Astragalus membranaceus

Astragalus membranaceus(AM)at a rate of 2.8g three times per day

OTHERPlacebo

at a rate of 2.8g three times per day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Gender: Male or female. 2. Age: between 40 and 80 years old. 3. Three months after stroke. 4. Hemorrhagic stroke or ischemic stroke. 5. Fatigue score from screen process ≧4. 6. Subject with comprehension or communication. 7. Volunteer signs the agreement to participate the study after whole study purpose and procedures description in detail.

Exclusion criteria

1. People from mental illness can not to participate the evaluation. 2. Major diseases such as cancer、Chronic pulmonary obstructive disease(COPD)、 Heart failure、Myocardial Infraction、Chronic renal failure or Liver cirrhosis. 3. Pregnant woman. 4. Breast-feeding woman.

Design outcomes

Primary

Measure	Time frame
EORTC QLQ-C30	2 year(all patients)
BFI-T score	2 years(all patients)

Secondary

Measure	Time frame
SF-36 score	2 years(all patients)

Countries

Taiwan

Contacts

Primary ContactChung Hsiang Liu, MD.

greengen@gmail.com886-4-22052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026